<DOC>
	<DOCNO>NCT00269672</DOCNO>
	<brief_summary>There evidence aluminum phosphate ( AlPO4 ) contain adjuvant conjugate vaccine enhances immune response infant . There data far evaluate whether also apply adult . The objective study compare immune response 2 different 13-valent pneumococcal conjugate ( 13vPnC ) formulation without AlPO4 select formulation compare immune response choose 13vPnC formulation relative immune response 23-valent pneumococcal polysaccharide vaccine ( 23vPS ) .</brief_summary>
	<brief_title>Study Evaluate 13-valent Pneumococcal Conjugate Vaccine Elderly Subjects</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Male female adult 65 year age old . Determined medical history , physical examination , clinical judgment eligible study . Expected available duration trial ( approximately 13 month ) . Received previous immunization 23vPS . Serious chronic disorder include metastatic malignancy Known suspect hypersensitivity vaccine vaccine component</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>vaccine</keyword>
</DOC>